176 related articles for article (PubMed ID: 28591560)
1. Implications of the lysophosphatidic acid signaling axis in liver cancer.
Lopane C; Agosti P; Gigante I; Sabbà C; Mazzocca A
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):277-282. PubMed ID: 28591560
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression.
Park SY; Jeong KJ; Panupinthu N; Yu S; Lee J; Han JW; Kim JM; Lee JS; Kang J; Park CG; Mills GB; Lee HY
Oncogene; 2011 Mar; 30(11):1351-9. PubMed ID: 21102517
[TBL] [Abstract][Full Text] [Related]
3. Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer.
Kaffe E; Magkrioti C; Aidinis V
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652837
[TBL] [Abstract][Full Text] [Related]
4. Lysophospholipid variants in hepatocellular carcinoma.
Skill NJ; Jianmin W; Yan X; Zhao Z; Tector AJ; Maluccio MA
J Surg Res; 2013 Jun; 182(2):241-9. PubMed ID: 23158405
[TBL] [Abstract][Full Text] [Related]
5. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.
Zuckerman V; Sokolov E; Swet JH; Ahrens WA; Showlater V; Iannitti DA; Mckillop IH
Oncotarget; 2016 Jan; 7(3):2951-67. PubMed ID: 26701886
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor.
Lou L; Chen YX; Jin L; Li X; Tao X; Zhu J; Chen X; Wu S; Ye W; He J; Ding G
J Int Med Res; 2013 Feb; 41(1):55-63. PubMed ID: 23569130
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through P38 MAPK pathway.
Zhu B; Shi S; Ma YG; Fan F; Yao ZZ
Hepatogastroenterology; 2012 May; 59(115):785-9. PubMed ID: 22020916
[TBL] [Abstract][Full Text] [Related]
8. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
Agosti P; Sabbà C; Mazzocca A
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma associated lipid metabolism reprogramming.
Skill NJ; Scott RE; Wu J; Maluccio MA
J Surg Res; 2011 Jul; 169(1):51-6. PubMed ID: 19932908
[TBL] [Abstract][Full Text] [Related]
11. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
12. Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis.
Xia Q; Deng AM; Wu SS; Zheng M
Acta Pharmacol Sin; 2011 Aug; 32(8):1055-62. PubMed ID: 21765444
[TBL] [Abstract][Full Text] [Related]
13. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma.
Chettouh H; Lequoy M; Fartoux L; Vigouroux C; Desbois-Mouthon C
Liver Int; 2015 Oct; 35(10):2203-17. PubMed ID: 26123841
[TBL] [Abstract][Full Text] [Related]
14. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels.
Enooku K; Uranbileg B; Ikeda H; Kurano M; Sato M; Kudo H; Maki H; Koike K; Hasegawa K; Kokudo N; Yatomi Y
PLoS One; 2016; 11(9):e0161825. PubMed ID: 27583415
[TBL] [Abstract][Full Text] [Related]
15. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.
Erstad DJ; Tager AM; Hoshida Y; Fuchs BC
Mol Cell Oncol; 2017; 4(3):e1311827. PubMed ID: 28616586
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid aberrancies and hepatocellular carcinoma: studies in the MDR2 gene knockout mouse.
Skill N; Wu J; Xu Y; Zhao Z; Maluccio M
Cancer Invest; 2013 Feb; 31(2):145-55. PubMed ID: 23362952
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin in liver fibrosis.
Ikeda H; Yatomi Y
Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
[TBL] [Abstract][Full Text] [Related]
18. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.
Weinmann A; Alt Y; Koch S; Nelles C; Düber C; Lang H; Otto G; Zimmermann T; Marquardt JU; Galle PR; Wörns MA; Schattenberg JM
BMC Cancer; 2015 Apr; 15():210. PubMed ID: 25884354
[TBL] [Abstract][Full Text] [Related]
19. The collagen triple helix repeat containing 1 facilitates hepatitis B virus-associated hepatocellular carcinoma progression by regulating multiple cellular factors and signal cascades.
Zhang R; Cao Y; Bai L; Zhu C; Li R; He H; Liu Y; Wu K; Liu F; Wu J
Mol Carcinog; 2015 Dec; 54(12):1554-66. PubMed ID: 25263696
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma.
Sokolov E; Eheim AL; Ahrens WA; Walling TL; Swet JH; McMillan MT; Simo KA; Thompson KJ; Sindram D; McKillop IH
J Surg Res; 2013 Mar; 180(1):104-13. PubMed ID: 23182454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
